戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rs, WHO performance status of 2, or elevated serum lactate dehydrogenase).
2 nced-stage disease, B symptoms, and elevated serum lactate dehydrogenase.
3 ted closely with hemolysis, as determined by serum lactate dehydrogenase.
4 s, abnormal cytogenetics, and high levels of serum lactate dehydrogenase and beta(2)-microglobulin as
5  had t(14;20), four (4%) of 100 had elevated serum lactate dehydrogenase, and 17 (17%) had two or mor
6 actors, such as volume and sites of disease, serum lactate dehydrogenase, and BRAF mutation status, a
7 te count, disease stage, performance status, serum lactate dehydrogenase, and number of extranodal si
8  deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation
9 esence/absence of liver and lung metastases, serum lactate dehydrogenase, blood neutrophil-lymphocyte
10 s (ie, age, tumor stage, performance status, serum lactate dehydrogenase concentration, and number of
11 operative Oncology Group performance status, serum lactate dehydrogenase concentration, and receipt o
12                                          The serum lactate dehydrogenase concentrations and the alveo
13 with BL, age 40 years, performance status 2, serum lactate dehydrogenase > 3x upper limit of normal,
14 ow Karnofsky performance status (<80%), high serum lactate dehydrogenase (&gt; 1.5 times upper limit of
15  thrombocytopenia (<20,000/microl), elevated serum lactate dehydrogenase (&gt;1,500U/liter), schistocyto
16 oliferation and apoptosis markers as well as serum lactate dehydrogenase isoenzyme 1 (S-LD-1) may hav
17  [HR], 1.9 [95% CI, 1.2 to 2.1]; P = .0009), serum lactate dehydrogenase (LDH) above upper limit of n
18 jury was of sufficient magnitude to increase serum lactate dehydrogenase (LDH) and was oxidative in n
19  opportunistic pneumonia had a higher median serum lactate dehydrogenase (LDH) concentration than did
20  these patients were median age of 56 years; serum lactate dehydrogenase (LDH) greater than 1N, 60%;
21 data showed that a lower pre-lymphodepletion serum lactate dehydrogenase (LDH) level and a favorable
22           Furthermore, it is unclear whether serum lactate dehydrogenase (LDH) level, commonly ordere
23                Tumor burden was estimated by serum lactate dehydrogenase (LDH) measurement and reclas
24 e of liver metastases and elevated levels of serum lactate dehydrogenase (LDH) offered superior progn
25 seen even in the elderly, in those with high serum lactate dehydrogenase (LDH) or beta2-microglobulin
26 ion after CD138 plasma cell purification and serum lactate dehydrogenase (LDH) to evaluate their prog
27                       Importantly, increased serum lactate dehydrogenase (LDH) was identified as an a
28     RT-PCR results were also correlated with serum lactate dehydrogenase (LDH), treatment status, and
29  status, liver metastases, disease site, and serum lactate dehydrogenase (LDH).
30 ity and markers of hemolysis, in particular, serum lactate dehydrogenase (LDH).
31 uded WHO performance status (0 v 1 or 2) and serum lactate dehydrogenase (LDH; </= v > 1.5x the upper
32               No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], beta(2) microglobulin
33 riable and multivariable analysis, increased serum lactate dehydrogenase level and histology for a me
34             Multivariate analysis identified serum lactate dehydrogenase level and the NOTCH1/FBXW7/R
35                            The pretransplant serum lactate dehydrogenase level was the most important
36 d normalization of platelet count, decreased serum lactate dehydrogenase level, and absence of new or
37 ent, significant nodal involvement, elevated serum lactate dehydrogenase level, and prognostic indica
38 n had poor-risk features defined as elevated serum lactate dehydrogenase level, stage IV, and bulky m
39 r visceral metastatic sites) and an elevated serum lactate dehydrogenase level.
40 ltivariate analysis including M substage and serum lactate dehydrogenase level.
41 osis, a decrease in hematocrit, and elevated serum lactate dehydrogenase levels were observed.
42 Patients with ES-SCLC, stratified by sex and serum lactate dehydrogenase levels, were randomly assign
43 n Arbor stage IV, low serum albumin and high serum lactate dehydrogenase levels.
44                    In patients with elevated serum lactate dehydrogenase (n = 84), median PFS and OS
45 e frequent in patients with normal levels of serum lactate dehydrogenase, no bone marrow involvement,
46 (P < .001), age >60 years (P < .001), raised serum lactate dehydrogenase (P = .005), and large-cell t
47 rular filtration rate levels, and had higher serum lactate dehydrogenase, procalcitonin, and interleu
48 btype, and correlated with disease stage and serum lactate dehydrogenase (R(s) = 0.79, P < .001).
49 , primary plasma cell leukaemia and elevated serum lactate dehydrogenase (two times the upper limit o
50                                              Serum lactate dehydrogenase was high in 35%, and beta-2